Germany · Delayed Price · Currency is EUR Addex Therapeutics Statistics
Total Valuation
FRA:APE has a market cap or net worth of EUR 7.83 million. The enterprise value is 5.38 million.
| Market Cap | 7.83M |
| Enterprise Value | 5.38M |
Important Dates
The next estimated earnings date is Monday, November 10, 2025.
| Earnings Date | Nov 10, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 111.25M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +9.98% |
| Shares Change (QoQ) | +2.21% |
| Owned by Insiders (%) | 23.61% |
| Owned by Institutions (%) | 2.18% |
| Float | 39.01M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 43.70 |
| PB Ratio | 1.01 |
| P/TBV Ratio | 1.01 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.83 |
| EV / Sales | 29.70 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -3.48 |
Financial Position
The company has a current ratio of 2.31, with a Debt / Equity ratio of 0.01.
| Current Ratio | 2.31 |
| Quick Ratio | 2.03 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.03 |
| Interest Coverage | -697.84 |
Financial Efficiency
Return on equity (ROE) is -61.91% and return on invested capital (ROIC) is -15.09%.
| Return on Equity (ROE) | -61.91% |
| Return on Assets (ROA) | -13.55% |
| Return on Invested Capital (ROIC) | -15.09% |
| Return on Capital Employed (ROCE) | -32.72% |
| Revenue Per Employee | 89,556 |
| Profits Per Employee | -3.24M |
| Employee Count | 2 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.05 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 49.66 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, FRA:APE had revenue of EUR 179,111 and -6.48 million in losses. Loss per share was -0.07.
| Revenue | 179,111 |
| Gross Profit | -527,956 |
| Operating Income | -2.58M |
| Pretax Income | -6.58M |
| Net Income | -6.48M |
| EBITDA | -2.49M |
| EBIT | -2.58M |
| Loss Per Share | -0.07 |
Balance Sheet
The company has 2.46 million in cash and 41,101 in debt, giving a net cash position of 2.42 million.
| Cash & Cash Equivalents | 2.46M |
| Total Debt | 41,101 |
| Net Cash | 2.42M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 7.72M |
| Book Value Per Share | 0.07 |
| Working Capital | 1.61M |
Cash Flow
In the last 12 months, operating cash flow was -1.54 million and capital expenditures -1,363, giving a free cash flow of -1.54 million.
| Operating Cash Flow | -1.54M |
| Capital Expenditures | -1,363 |
| Free Cash Flow | -1.54M |
| FCF Per Share | n/a |
Margins
| Gross Margin | -294.77% |
| Operating Margin | -1,438.85% |
| Pretax Margin | -3,675.86% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:APE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.98% |
| Shareholder Yield | -9.98% |
| Earnings Yield | -82.75% |
| FCF Yield | -19.72% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
FRA:APE has an Altman Z-Score of -56.56 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -56.56 |
| Piotroski F-Score | 1 |